-
1
-
-
0033524482
-
A two-step, two-signal model for the primary activation of precursor helper T cells
-
Bretscher PA. 1999. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc. Natl. Acad. Sci. USA 96(1):185-90
-
(1999)
Proc. Natl. Acad. Sci. USA
, vol.96
, Issue.1
, pp. 185-190
-
-
Bretscher, P.A.1
-
2
-
-
0032502801
-
Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
-
Van Parijs L, Abbas AK. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280(5361):243-48
-
(1998)
Science
, vol.280
, Issue.5361
, pp. 243-248
-
-
Van Parijs, L.1
Abbas, A.K.2
-
3
-
-
0036156661
-
The role of novel T cell costimulatory pathways in autoimmunity and transplantation
-
Yamada A, Salama AD, Sayegh MH. 2002. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13(2):559-75
-
(2002)
J. Am. Soc. Nephrol
, vol.13
, Issue.2
, pp. 559-575
-
-
Yamada, A.1
Salama, A.D.2
Sayegh, M.H.3
-
4
-
-
0032543306
-
The role of T-cell costimulatory activation pathways in transplant rejection
-
Sayegh MH, Turka LA. 1998. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338(25):1813-21
-
(1998)
N. Engl. J. Med
, vol.338
, Issue.25
, pp. 1813-1821
-
-
Sayegh, M.H.1
Turka, L.A.2
-
5
-
-
0032996025
-
Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
-
Kirk AD, Burkly LC, Batty DS, et al. 1999. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5(6):686-93
-
(1999)
Nat. Med
, vol.5
, Issue.6
, pp. 686-693
-
-
Kirk, A.D.1
Burkly, L.C.2
Batty, D.S.3
-
6
-
-
0036130828
-
CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism
-
Andre P, Prasad KS, Denis CV, et al. 2002. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat. Med. 8(3):247-52
-
(2002)
Nat. Med
, vol.8
, Issue.3
, pp. 247-252
-
-
Andre, P.1
Prasad, K.S.2
Denis, C.V.3
-
7
-
-
0027403299
-
The role of the CD28 receptor during T cell responses to antigen
-
Linsley PS, Ledbetter JA. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191-212
-
(1993)
Annu. Rev. Immunol
, vol.11
, pp. 191-212
-
-
Linsley, P.S.1
Ledbetter, J.A.2
-
10
-
-
0035101515
-
CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis
-
Kim KS, Denton MD, Chandraker A, et al. 2001. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158(3):977-86
-
(2001)
Am. J. Pathol
, vol.158
, Issue.3
, pp. 977-986
-
-
Kim, K.S.1
Denton, M.D.2
Chandraker, A.3
-
11
-
-
0026486220
-
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
-
Linsley PS, Greene JL, Tan P, et al. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176(6):1595-604
-
(1992)
J. Exp. Med
, vol.176
, Issue.6
, pp. 1595-1604
-
-
Linsley, P.S.1
Greene, J.L.2
Tan, P.3
-
12
-
-
0027937702
-
Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1
-
Peach RJ, Bajorath J, Brady W, et al. 1994. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180(6):2049-58
-
(1994)
J. Exp. Med
, vol.180
, Issue.6
, pp. 2049-2058
-
-
Peach, R.J.1
Bajorath, J.2
Brady, W.3
-
13
-
-
0028675006
-
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
-
Linsley PS, Greene JL, Brady W, et al. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1(9):793-801
-
(1994)
Immunity
, vol.1
, Issue.9
, pp. 793-801
-
-
Linsley, P.S.1
Greene, J.L.2
Brady, W.3
-
14
-
-
0029914089
-
Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions
-
Greene JL, Leytze GM, Emswiler J, et al. 1996. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271(43):26762-71
-
(1996)
J. Biol. Chem
, vol.271
, Issue.43
, pp. 26762-26771
-
-
Greene, J.L.1
Leytze, G.M.2
Emswiler, J.3
-
16
-
-
4444369694
-
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
-
Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. 2004. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21(3):401-13
-
(2004)
Immunity
, vol.21
, Issue.3
, pp. 401-413
-
-
Pentcheva-Hoang, T.1
Egen, J.G.2
Wojnoonski, K.3
Allison, J.P.4
-
17
-
-
0029871741
-
The in vivo mechanism of action of CTLA4Ig
-
Judge TA, Tang A, Spain LM, Deans-Gratiot J, Sayegh MH, Turka LA. 1996. The in vivo mechanism of action of CTLA4Ig. J. Immunol. 156(6):2294-99
-
(1996)
J. Immunol
, vol.156
, Issue.6
, pp. 2294-2299
-
-
Judge, T.A.1
Tang, A.2
Spain, L.M.3
Deans-Gratiot, J.4
Sayegh, M.H.5
Turka, L.A.6
-
18
-
-
0026738641
-
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg
-
Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257(5071):789-92
-
(1992)
Science
, vol.257
, Issue.5071
, pp. 789-792
-
-
Lenschow, D.J.1
Zeng, Y.2
Thistlethwaite, J.R.3
-
19
-
-
0028365181
-
Transplantation tolerance induced by CTLA4-Ig
-
Pearson TC, Alexander DZ, Winn KJ, et al. 1994. Transplantation tolerance induced by CTLA4-Ig. Transplantation 57(12):1701-6
-
(1994)
Transplantation
, vol.57
, Issue.12
, pp. 1701-1706
-
-
Pearson, T.C.1
Alexander, D.Z.2
Winn, K.J.3
-
20
-
-
20044386299
-
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties
-
Larsen CP, Pearson TC, Adams AB, et al. 2005. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3):443-53
-
(2005)
Am. J. Transplant
, vol.5
, Issue.3
, pp. 443-453
-
-
Larsen, C.P.1
Pearson, T.C.2
Adams, A.B.3
-
21
-
-
0029849012
-
Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: Requirement for both B7-1 and B7-2
-
Webb LM, Walmsley MJ, Feldmann M. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26(10):2320-28
-
(1996)
Eur. J. Immunol
, vol.26
, Issue.10
, pp. 2320-2328
-
-
Webb, L.M.1
Walmsley, M.J.2
Feldmann, M.3
-
22
-
-
0028483990
-
Treatment of murine lupus with CTLA4Ig
-
Finck BK, Linsley PS, Wofsy D. 1994. Treatment of murine lupus with CTLA4Ig. Science 265(5176):1225-27
-
(1994)
Science
, vol.265
, Issue.5176
, pp. 1225-1227
-
-
Finck, B.K.1
Linsley, P.S.2
Wofsy, D.3
-
23
-
-
0028800090
-
The epidemiology of drug treatment failure in rheumatoid arthritis
-
Wolfe F. 1995. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin. Rheumatol. 9(4):619-32
-
(1995)
Baillieres Clin. Rheumatol
, vol.9
, Issue.4
, pp. 619-632
-
-
Wolfe, F.1
-
24
-
-
0035883897
-
Rheumatoid arthritis
-
Lee DM, Weinblatt ME. 2001. Rheumatoid arthritis. Lancet 358(9285):903-11
-
(2001)
Lancet
, vol.358
, Issue.9285
, pp. 903-911
-
-
Lee, D.M.1
Weinblatt, M.E.2
-
25
-
-
0020039524
-
Augmented numbers of HLA-DR-positive T lymphocytes in the synovial fluid and synovial tissue of patients with rheumatoid arthritis and juvenile rheumatoid arthritis: In vivo-activated T lymphocytes are potent stimulators in the mixed lymphocyte reaction
-
Forre O, Dobloug JH, Natvig JB. 1982. Augmented numbers of HLA-DR-positive T lymphocytes in the synovial fluid and synovial tissue of patients with rheumatoid arthritis and juvenile rheumatoid arthritis: in vivo-activated T lymphocytes are potent stimulators in the mixed lymphocyte reaction. Scand J. Immunol. 15(2):227-31
-
(1982)
Scand J. Immunol
, vol.15
, Issue.2
, pp. 227-231
-
-
Forre, O.1
Dobloug, J.H.2
Natvig, J.B.3
-
26
-
-
0019411775
-
Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates
-
Konttinen YT, Reitamo S, Ranki A, et al. 1981. Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates. Arthritis Rheum. 24(1):71-79
-
(1981)
Arthritis Rheum
, vol.24
, Issue.1
, pp. 71-79
-
-
Konttinen, Y.T.1
Reitamo, S.2
Ranki, A.3
-
27
-
-
0141427819
-
Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: A matched observational study
-
Aletaha D, Stamm T, Kapral T, et al. 2003. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann. Rheum. Dis. 62(10):944-51
-
(2003)
Ann. Rheum. Dis
, vol.62
, Issue.10
, pp. 944-951
-
-
Aletaha, D.1
Stamm, T.2
Kapral, T.3
-
28
-
-
19044375758
-
Effective use of TNF antagonists
-
Yocum D. 2004. Effective use of TNF antagonists. Arthritis Res. Ther. 6 (Suppl. 2):S24-30
-
(2004)
Arthritis Res. Ther
, vol.6
, Issue.SUPPL. 2
-
-
Yocum, D.1
-
29
-
-
10944261085
-
Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
-
Schwartzman S, Fleischmann R, Morgan GJ Jr. 2004. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res. Ther. 6 (Suppl. 2):S3-S11
-
(2004)
Arthritis Res. Ther
, vol.6
, Issue.SUPPL. 2
-
-
Schwartzman, S.1
Fleischmann, R.2
Morgan Jr., G.J.3
-
30
-
-
0012469264
-
-
United States Food and Drug Administration, Americans with Disabilities Act Committee, Accessed Sep. 7
-
United States Food and Drug Administration, Americans with Disabilities Act Committee. 2006. Safety update on TNF antagonists: infliximab and etanercept. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2.htm. Accessed Sep. 7, 2006
-
(2006)
Safety update on TNF antagonists: Infliximab and etanercept
-
-
-
31
-
-
1642540027
-
Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: Dose adjustments are common but not always sufficient to assure sustained benefit
-
Sidiropoulos P, Bertsias G, Kritikos HD, et al. 2004. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann. Rheum. Dis. 63(2):144-48
-
(2004)
Ann. Rheum. Dis
, vol.63
, Issue.2
, pp. 144-148
-
-
Sidiropoulos, P.1
Bertsias, G.2
Kritikos, H.D.3
-
32
-
-
0033135564
-
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
-
Abrams JR, Lebwohl MG, Guzzo CA, et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103(9):1243-52
-
(1999)
J. Clin. Invest
, vol.103
, Issue.9
, pp. 1243-1252
-
-
Abrams, J.R.1
Lebwohl, M.G.2
Guzzo, C.A.3
-
33
-
-
23644455857
-
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial
-
Kremer JM, Dougados M, Emery P, et al. 2005. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(8):2263-71
-
(2005)
Arthritis Rheum
, vol.52
, Issue.8
, pp. 2263-2271
-
-
Kremer, J.M.1
Dougados, M.2
Emery, P.3
-
34
-
-
0242574700
-
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
-
Kremer JM, Westhovens R, Leon M, et al. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20):1907-15
-
(2003)
N. Engl. J. Med
, vol.349
, Issue.20
, pp. 1907-1915
-
-
Kremer, J.M.1
Westhovens, R.2
Leon, M.3
-
35
-
-
33745291091
-
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial
-
Kremer JM, Genant HK, Moreland LW, et al. 2006. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12):865-76
-
(2006)
Ann. Intern. Med
, vol.144
, Issue.12
, pp. 865-876
-
-
Kremer, J.M.1
Genant, H.K.2
Moreland, L.W.3
-
36
-
-
34248159251
-
Abatacept provides sustained clinical benefit through 3 years in rheumatoid arthritis patients with inadequate responses to methotrexate
-
Abstr. SAT0203
-
Westhovens R, Emery P, Aranda R, et al. 2006. Abatacept provides sustained clinical benefit through 3 years in rheumatoid arthritis patients with inadequate responses to methotrexate. Ann. Rheum. Dis. 65(Suppl. II):512, Abstr. SAT0203
-
(2006)
Ann. Rheum. Dis
, vol.65
, Issue.SUPPL. II
, pp. 512
-
-
Westhovens, R.1
Emery, P.2
Aranda, R.3
-
37
-
-
34248187386
-
-
Genant HK, Peterfy C, Wu C, et al. 2005. An ACR 20 response is not required for inhibition of structural damage progression by abatacept: results from the AIM Trial. Arthritis Rheum. 52(9 Suppl.):S350, Abstr. 1991
-
Genant HK, Peterfy C, Wu C, et al. 2005. An ACR 20 response is not required for inhibition of structural damage progression by abatacept: results from the AIM Trial. Arthritis Rheum. 52(9 Suppl.):S350, Abstr. 1991
-
-
-
-
38
-
-
33750992180
-
Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis
-
Weisman MH, Durez P, Hallegua D, et al. 2006. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J. Rheumatol. 33:2162-66
-
(2006)
J. Rheumatol
, vol.33
, pp. 2162-2166
-
-
Weisman, M.H.1
Durez, P.2
Hallegua, D.3
-
39
-
-
24944498854
-
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
-
Genovese M, Becker J-C, Schiff M, et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11):1114-23
-
(2005)
N. Engl. J. Med
, vol.353
, Issue.11
, pp. 1114-1123
-
-
Genovese, M.1
Becker, J.-C.2
Schiff, M.3
-
40
-
-
33749365296
-
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study
-
Weinblatt ME, Combe B, Covucci A, et al. 2006. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Res. 54:2807-16
-
(2006)
Arthritis Res
, vol.54
, pp. 2807-2816
-
-
Weinblatt, M.E.1
Combe, B.2
Covucci, A.3
-
41
-
-
34248204412
-
-
Moreland LW, Combe B, Steinfeld SD, et al. 2005. An integrated safety analysis of abatacept in the treatment of rheumatoid arthritis (RA) across patient types and background therapies. Arthritis Rheum. 52(9 Suppl.):S350, Abstr. 886
-
Moreland LW, Combe B, Steinfeld SD, et al. 2005. An integrated safety analysis of abatacept in the treatment of rheumatoid arthritis (RA) across patient types and background therapies. Arthritis Rheum. 52(9 Suppl.):S350, Abstr. 886
-
-
-
-
42
-
-
34248148394
-
-
UNOS
-
UNOS. 2006. http://www.unos.org/
-
(2006)
-
-
-
43
-
-
0042360213
-
Chronic renal failure after transplantation of a nonrenal organ
-
Ojo AO, Held PJ, Port FK, et al. 2003. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349(10):931-40
-
(2003)
N. Engl. J. Med
, vol.349
, Issue.10
, pp. 931-940
-
-
Ojo, A.O.1
Held, P.J.2
Port, F.K.3
-
44
-
-
0031586439
-
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group
-
Nashan B, Moore R, Amlot P, et al. 1997. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350(9086):1193-98
-
(1997)
Lancet
, vol.350
, Issue.9086
, pp. 1193-1198
-
-
Nashan, B.1
Moore, R.2
Amlot, P.3
-
45
-
-
12644262358
-
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
-
Kirk AD, Harlan DM, Armstrong NN, et al. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94(16):8789-94
-
(1997)
Proc. Natl. Acad. Sci. USA
, vol.94
, Issue.16
, pp. 8789-8794
-
-
Kirk, A.D.1
Harlan, D.M.2
Armstrong, N.N.3
-
46
-
-
0031307384
-
Immunosuppressive effects of human CTLA4Ig in a nonhuman primate model of allogeneic pancreatic islet transplantation
-
Levisetti MG, Padrid PA, Szot GL, et al. 1997. Immunosuppressive effects of human CTLA4Ig in a nonhuman primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159(11):5187-91
-
(1997)
J. Immunol
, vol.159
, Issue.11
, pp. 5187-5191
-
-
Levisetti, M.G.1
Padrid, P.A.2
Szot, G.L.3
-
48
-
-
0028826268
-
Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies
-
Lenschow DJ, Zeng Y, Hathcock KS, et al. 1995. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 60(10):1171-78
-
(1995)
Transplantation
, vol.60
, Issue.10
, pp. 1171-1178
-
-
Lenschow, D.J.1
Zeng, Y.2
Hathcock, K.S.3
-
49
-
-
20044386299
-
Rational development of LEA29Y, a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties
-
Larsen CP, Pearson TC, Adams AB, et al. 2005. Rational development of LEA29Y, a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3)443-53
-
(2005)
Am. J. Transplant
, vol.5
, Issue.3
, pp. 443-453
-
-
Larsen, C.P.1
Pearson, T.C.2
Adams, A.B.3
-
50
-
-
23944502334
-
Costimulation blockade with belatacept in renal transplantation
-
Vincenti F, Larsen C, Durrbach A, et al. 2005. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353(8):770-81
-
(2005)
N. Engl. J. Med
, vol.353
, Issue.8
, pp. 770-781
-
-
Vincenti, F.1
Larsen, C.2
Durrbach, A.3
-
51
-
-
0036314948
-
Post-transplant renal function in the first year predicts long-term kidney transplant survival
-
Hariharan S, McBride MA, Cherikh WS, et al. 2002. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 62(1):311-18
-
(2002)
Kidney Int
, vol.62
, Issue.1
, pp. 311-318
-
-
Hariharan, S.1
McBride, M.A.2
Cherikh, W.S.3
-
52
-
-
4143127834
-
Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology
-
Nankivell BJ, Borrows RJ, Fung CL, et al. 2004. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78(4):557-65
-
(2004)
Transplantation
, vol.78
, Issue.4
, pp. 557-565
-
-
Nankivell, B.J.1
Borrows, R.J.2
Fung, C.L.3
-
53
-
-
16444362802
-
Combating chronic renal allograft dysfunction: Optimal immunosuppressive regimens
-
Merville P. 2005. Combating chronic renal allograft dysfunction: optimal immunosuppressive regimens. Drugs 65(5):615-31
-
(2005)
Drugs
, vol.65
, Issue.5
, pp. 615-631
-
-
Merville, P.1
-
54
-
-
0036766652
-
Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor
-
Rosengard BR, Feng S, Alfrey EJ, et al. 2002. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am. J. Transplant. 2(8):701-11
-
(2002)
Am. J. Transplant
, vol.2
, Issue.8
, pp. 701-711
-
-
Rosengard, B.R.1
Feng, S.2
Alfrey, E.J.3
|